ripekg:evaluation/RIPEA49DCC9BA0CF06921 |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:evidence-aggregation/RIPEA49DCC9BA0CF06921 |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:integrity-assessment-hypothesis/RIPEA49DCC9BA0CF06921-human-1-1 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:integrity-assessment-hypothesis/RIPEA49DCC9BA0CF06921-human-1-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:integrity-assessment-hypothesis/RIPEA49DCC9BA0CF06921-human-1-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:integrity-assessment-hypothesis/RIPEA49DCC9BA0CF06921-human-2-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:integrity-assessment-hypothesis/RIPEA49DCC9BA0CF06921-human-overall |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:integrity-assessment-hypothesis/RIPEA49DCC9BA0CF06921-inspectai-1-1 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:integrity-assessment-hypothesis/RIPEA49DCC9BA0CF06921-inspectai-1-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:integrity-assessment-hypothesis/RIPEA49DCC9BA0CF06921-inspectai-1-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:integrity-assessment-hypothesis/RIPEA49DCC9BA0CF06921-inspectai-2-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:publication-details/RIPEA49DCC9BA0CF06921Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:registry-evidence/RIPEA49DCC9BA0CF06921 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
rdf:type |
rdfs:Resource |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
rdf:type |
owl:Thing |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
rdf:type |
ripe:ResearchIntegrityAssessmentResearch integrity assessment |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
rdf:type |
tido:Case |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripe:assesses |
ripekg:work/10.1136%2Fannrheumdis-2014-205698Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:integrity-assessment-question/post-publication-notices/1.0.01.2. Does the study have an associated expression of concern or other relevant post-publication notice? |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:integrity-assessment-question/post-publication-notices/1.0.0post-publication notices |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.01.3. Do other studies by the research team highlight causes for concern? |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.0research-team-related concerns |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:integrity-assessment-question/retraction-status/1.0.01.1. Does the study have an associated retraction? |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:integrity-assessment-question/retraction-status/1.0.0retraction status |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:integrity-assessment-question/study-registration/1.0.02.2. Are there concerns relating to the timing or absence of study registration? |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:integrity-assessment-question/study-registration/1.0.0study registration |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:overall-integrity-assessment-question/1.0.0What is the overall integrity assessment of the study? |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
tido:investigates |
ripekg:overall-integrity-assessment-question/1.0.0overall integrity assessment |
ripekg:retraction-notice/19710Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |
ripekg:study-design-evidence/RIPEA49DCC9BA0CF06921 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA49DCC9BA0CF06921 |